首页> 外文期刊>Oncology and Therapy >The Patient Perspective on Living with Acute Myeloid Leukemia
【24h】

The Patient Perspective on Living with Acute Myeloid Leukemia

机译:急性髓细胞白血病患者的患者观点

获取原文
       

摘要

Introduction Acute myeloid leukemia (AML) imposes significant burden on patients, their families, and the healthcare system. Published literature has reported many AML signs and symptoms, as well as their impact on patients. However, there are no publications on the experience of living with AML from the patient's perspective. In this study, we performed qualitative interviews with patients with AML to understand their experience. Methods Participants were recruited from the US and Japan. All patients were screened to assess eligibility, and were divided into four subgroups (i.e., newly-diagnosed, high-intensity chemotherapy; newly-diagnosed, low-intensity chemotherapy; relapse/refractory; and post-transplant). Patients were interviewed over the phone by a trained researcher and asked about their day-to-day experience with AML. Signs/symptoms and impacts were coded, analyzed using Atlas.ti software, and reported as frequencies, with the medians of patient-reported disturbance levels (0–10) computed for each symptom and impact. Results The most commonly reported sign/symptom in the US was fatigue (95.7%), followed by bruising and weakness (both 78.3%), and in Japan, nausea (94.4%), followed by fatigue and headache (both 88.9%). The most commonly reported impact in the US was a decreased ability to maintain social/familial roles (91.3%), followed by anxiety and a decreased ability to function (both 87.0%), and most commonly reported in Japan was anxiety, a decreased ability to function, and remission uncertainty (94.4%). Conclusion Although the frequency of signs/symptoms and their level of disturbance varied between the US and Japan, there was remarkable consistency in the types of signs/symptoms and impacts reported across all patients. The consistency in the experience of the disease across patients suggests that measurement of AML experience can be achieved by using the same tool for most, if not all, of these patients. Funding Astellas Pharma Inc., Northbrook, IL, USA.
机译:简介急性髓细胞性白血病(AML)给患者,他们的家人和医疗保健系统带来了沉重负担。公开的文献已经报道了许多AML的体征和症状,以及它们对患者的影响。但是,从患者的角度来看,没有关于AML生存经历的出版物。在这项研究中,我们对AML患者进行了定性访谈,以了解他们的经验。方法从美国和日本招募参与者。筛选所有患者以评估其资格,并将其分为四个亚组(即,新诊断的高强度化疗;新诊断的低强度化疗;复发/难治性和移植后)。受过训练的研究人员通过电话采访了患者,并询问了他们在AML方面的日常经验。对体征/症状和影响进行编码,使用Atlas.ti软件进行分析,并以频率报告,并针对每种症状和影响计算出患者报告的干扰水平的中位数(0-10)。结果在美国,最常见的体征/症状是疲劳(95.7%),其次是瘀伤和无力(均为78.3%),在日本,恶心(94.4%),其次是疲劳和头痛(均为88.9%)。在美国,最常见的影响是保持社交/家庭角色的能力下降(91.3%),其次是焦虑和功能下降(均为87.0%),在日本,最常见的是焦虑,能力下降发挥作用,缓解不确定性(94.4%)。结论尽管在美国和日本之间,体征/症状的频率及其干扰程度有所不同,但在所有患者中报告的体征/症状和影响类型均具有显着一致性。跨患者的疾病经验的一致性表明,对于大多数(如果不是全部)这些患者,使用相同的工具可以测量AML经验。资助美国伊利诺斯州诺斯布鲁克的Astellas Pharma Inc.。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号